LTBR rs2364480 — A Coding Variant in the Lymphotoxin-Beta Receptor
The lymphotoxin-beta receptor (LTBR, also known as TNFRSF3) is a cell-surface receptor of the
tumor necrosis factor receptor superfamily11 tumor necrosis factor receptor superfamily
TNFRSF members are structurally related receptors that
bind TNF-family cytokines and regulate inflammation, cell survival, and lymphoid organ
development that governs how your immune cells build
and maintain organized lymphoid architecture. LTBR sits at the hub of a signaling network that tells
stromal cells to differentiate into the specialized vasculature and reticular scaffolds that make lymph
nodes, Peyer's patches, and other secondary lymphoid organs function. Without proper LTBR signaling,
these structures fail to form — and without well-organized lymphoid tissue, the immune system cannot
mount ordered, antigen-specific responses.
rs2364480 is a synonymous coding variant in LTBR on chromosome 12p13.31: the nucleotide change
(C→A at position 6386109, GRCh38) does not alter the alanine at protein position 172, but synonymous
variants are not necessarily silent. They can affect codon usage and translation kinetics22 codon usage and translation kinetics
Different codons for the same amino acid are translated at different speeds; slower translation at
critical points can alter how the protein folds co-translationally,
mRNA stability, and splicing efficiency — mechanisms that have been documented for synonymous SNPs in
other immune-receptor genes.
The Mechanism
LTBR receives signals from two main ligands: the lymphotoxin-αβ heterodimer (LTα1β2) secreted by
activated T and B cells, and LIGHT (TNFSF14) expressed on activated T cells and NK cells. Upon
ligation, LTBR activates two parallel NF-κB pathways33 NF-κB pathways
NF-κB is a master transcription factor
controlling inflammation, immune development, and cell survival — LTBR uniquely activates both the
canonical (RelA/p50) and the non-canonical (RelB/p52) arms.
The canonical arm drives acute inflammatory gene expression (IL-8, chemokines). The non-canonical arm,
requiring NIK and IKKα, controls expression of chemokines (CXCL13, CCL19, CCL21) that recruit and
position lymphocytes for optimal antigen encounters. This non-canonical pathway is also responsible for
LTBR's critical role in lymph node organogenesis and tertiary lymphoid structure formation.
In rheumatoid arthritis, LTBR is overexpressed in synovial tissue44 LTBR is overexpressed in synovial tissue
In one study correlating synovial
cytokine expression with clinical measures, LTBR mRNA positively correlated with TNF-α, IFN-γ, and
IL-15 levels, suggesting a feedback amplification loop in inflamed
joints, where excess LTBR signaling drives formation of
ectopic lymphoid tissue (ELT) — structures resembling lymph nodes that sustain local autoimmune
responses. In IgA nephropathy, LTBR protein is detected in renal tubular epithelial cells and glomeruli55 LTBR protein is detected in renal tubular epithelial cells and glomeruli
Induction of LTβ mRNA was identified in microarrays from both IgAN and lupus nephritis patients,
and LTβR-Ig treatment attenuated nephritis severity in animal models,
where it drives local NF-κB activation and renal inflammatory cascades.
The Evidence
The strongest genetic evidence for the LTBR locus in autoimmunity comes from a landmark
GWAS of ankylosing spondylitis66 GWAS of ankylosing spondylitis
The Australo-Anglo-American Spondyloarthritis Consortium (TASC)
and Wellcome Trust Case Control Consortium 2 (WTCCC2) combined ~10,000 AS patients and controls
in the largest AS genetic study at the
time: the LTBR-TNFRSF1A region on chromosome 12p13
was associated with AS at genome-wide significance (rs11616188, combined P=4.1×10⁻¹²). This
implicates the LTBR locus — not a single variant, but a chromosomal neighborhood of immune-signaling
genes — in the genetic architecture of spondyloarthropathy.
For rs2364480 specifically, a Korean pediatric study77 Korean pediatric study
199 children with biopsy-confirmed IgA nephropathy
and 289 age-matched controls, genotyped by direct sequencing
found the C allele of rs2364480 nominally associated with IgAN risk (p=0.041). The haplotype
analysis was stronger: the TAA haplotype spanning rs3759333, rs3759334, and rs2364480 was significantly
associated with IgAN (p=0.008 codominant). These findings are modest in isolation — a single study
in one population with borderline p-values — but they are biologically coherent with the known role
of LTBR in renal inflammation and the GWAS evidence at the broader locus.
Therapeutically, baminercept88 baminercept
A fusion protein of the LTβR extracellular domain with human IgG1 Fc;
it acts as a decoy receptor, capturing lymphotoxin and LIGHT before they reach cell-surface
LTBR — an LTβR-Ig fusion protein — was tested in a Phase II
RCT for primary Sjögren's syndrome (52 patients, 24 weeks). While baminercept mechanistically reduced
CXCL13 and altered B/T cell trafficking consistent with LTβR blockade, it did not significantly
improve glandular endpoints. This underscores the complexity of LTBR signaling in established
autoimmune disease, but also validates that LTBR is a genuine pharmacological target in this pathway.
Practical Implications
Carriers of the CC genotype (the minor/risk genotype at ~4% frequency globally) carry two copies of the less-common C allele, which in the haplotype context associates with modestly altered LTBR signaling and nominal IgAN susceptibility in the published literature. For heterozygous AC carriers (~31%), the evidence for any clinically meaningful impact is limited; the current data support a monitoring posture rather than active intervention. For the common AA genotype (~65%), the population default — normal LTBR signaling and no signal for elevated autoimmune risk from this specific variant.
Interactions
rs2364480 sits within a haplotype block studied alongside the LTBR promoter variants rs3759333 (-1387C/T) and rs3759334 (-1326A/G). The TAA haplotype (rs3759333-T / rs3759334-A / rs2364480-A, using the Korean study's minor-allele notation) showed the strongest IgAN association (p=0.008), suggesting these three variants act together to modulate LTBR promoter activity and coding-region translational efficiency. The existing LTBR catalog entry rs10849448 (a 5'UTR regulatory variant with strong evidence for infection susceptibility) represents a distinct functional signal at the same gene — the two variants are not in tight LD and likely affect different aspects of LTBR biology.
The LTBR-TNFRSF1A chromosomal neighborhood (12p13) is a genetic hub for TNF-superfamily signaling. Carriers of risk alleles at TNFRSF1A (rs4149584, encoding R92Q in TNF receptor 1) combined with rs2364480 CC may face a compounded deficit in TNF-family receptor regulation — a proposed compound action candidate warranting future investigation.